• CSL Ltd., of King of Prussia, Pa., presented data at the American Heart Association meeting in Dallas showing that CSL112 demonstrated favorable safety and tolerability when administered to patients with stable atherothrombotic disease and showed a dramatic and rapid increase in key biomarkers of reverse cholesterol transport.